| P/E (FY) | — | Sales (TTM) | $43.2M |
| Earnings (TTM) | -$11.1M | ROE | −141.30% |
| Net Margin | −25.26% | ROIC | −685.39% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 13.30% |
| Market Cap | $14.2M | Trading Days | 941 |
| 52W High | 1.21 |
| 52W Low | 0.56 |
| % Off High | −7.88% |
| YTD | 94.74% | 1Y | 3.74% |
| 3Y | −90.74% | Since incept. (ann.) | −55.99% |
| Ann. Volatility (1Y) | 78.78% | Ann. Volatility (3Y) | 108.14% |
| Sharpe (1Y) | 0.43 | Sharpe (3Y) | −0.23 |
| Max Drawdown (1Y) | −50.86% | Max Drawdown (3Y) | −95.45% |
| Beta (3Y, vs SPY) | 0.19 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| HIND | Vyome Holdings, Inc | $14.0M | — |
| CTXR | Citius Pharmaceuticals, Inc. | $13.7M | — |
| ANEB | Anebulo Pharmaceuticals, Inc. | $13.5M | — |
| KTTA | Pasithea Therapeutics Corp. | $15.0M | — |
| LEXX | Lexaria Bioscience Corp. | $13.4M | — |
| CYCN | Cyclerion Therapeutics, Inc. | $15.2M | — |
| SCNX | Scienture Holdings, Inc. | $15.2M | — |
| TPST | Tempest Therapeutics, Inc. | $12.9M | — |
| COCP | Cocrystal Pharma, Inc. | $12.9M | — |
| MBIO | MUSTANG BIO, INC. | $15.8M | — |
| MDCX | Medicus Pharma Ltd. |
| $15.9M |
| — |
| VYNE | VYNE Therapeutics Inc. | $17.0M | — |
